At a glance
ClinicalIndex Comparison RecordN/ACompleted· 11,157 enrolled
Drug / intervention
Tolterodine tartratedrug
Likely dose
Tolterodine tartrate 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Postmarketing Observational Study of Tolterodine Treatment on Overactive Bladder in Real Life Setting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Dec 8, 2011·Updated Jan 28, 2021
In Brief
An observational study evaluating Tolterodine tartrate for Overactive Bladder. Completed, enrolled 11,157 participants.
Detailed Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
Primary CompletionMar 2011
First PostedDec 2011
TodayJul 2026
First PostedDec 8, 2011
Enrollment StartDec 1, 2006
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 14.6 years ago
Interventions
Tolterodine tartratedrug
Detrusitol Capsule 2mg and 4mg, depending on the Investigator prescription.Frequency and duration are according to Package Insert as follows.